Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D
Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
It is the investigators hypothesis that participants treated with Ferric Citrate (FC) during
the non-dialysis CKD stage (4/5) with sufficient duration prior to initiating RRT, will
result in improved biochemical control of anemia (Hb, TSAT) and mineral metabolism (P, FGF23)
and furthermore, will result in a reduced need for ESA and intravenous iron. The
investigators further hypothesize that effective treatment of anemia and mineral metabolism
with FC in the pre-dialysis and transition period will result in improved physical
functioning, reduced hospitalization and reduced total cost of care when compared to
participants receiving contemporaneously provided standard of care therapy.